16Article 2(4) of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ 2008 L 334, p. 7), as amended by Commission Delegated Regulation (EU) 2021/756 of 24 March 2021 (OJ 2021 L 162, p. 1) (‘Regulation No 1234/2008’), provides that, for the purposes of that regulation, ‘extension of a marketing authorisation’ or ‘extension’ means a variation which is listed in Annex I and fulfils the conditions laid down therein.